Form D · Pharmaceuticals
M Pharmaceutical Inc.
Vancouver, A1 · CIK 0001687423
Offering snapshot reported Oct 25, 2016 · SEC filing
- Reported sold
- $25.8K Offering amount: $25.8K
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 7, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 25, 2016 | Initial | $25,832 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity, Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-273189
444,140 units were sold to US subscribers at C$0.075, a total amount of C$33,310.50. The rate of exchange of the C$, based on the noon buying rate as reported by the Federal Reserve Bank of New York on the date of the first sale, was C$1.00=US$0.7755.
Source: Form D, filed Oct 25, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Christopher Andrews | Director |
| Brian D. Keane | Executive |
| Tatiana Kovalena | Executive |
| Rick Skeith | Director |
| Gary Thompson | Executive |
| George Tsfalas | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
734 1055 Dunsmuir Street
Vancouver, A1, V7X 1B1
Vancouver, A1, V7X 1B1